Skip to content

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02000024
Enrollment
225
Registered
2013-12-03
Start date
2011-12-31
Completion date
2016-03-31
Last updated
2016-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes, Gestational Diabetes Mellitus, Obesity

Brief summary

This study is a randomized pilot study to assess the applicability of the Weight Watchers model for lifestyle modification to the primary prevention of type 2 diabetes. The approach developed by Weight Watchers to achieve weight loss is based on similar nutritional principals and techniques used in the Diabetes Prevention Program (DPP) lifestyle intervention; monitoring food intake, exercising calorie control, setting modest weight loss goals and using physical activity.

Detailed description

In the proposed study, the standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk. In many respects it mirrors the curriculum content used in the DPP with regards to themes and specific topics. There are significant differences, however, between the two approaches that warrant investigation. Weight Watchers uses a point system to help users select appropriate foods. This system is less focused on fat gram control as a central theme than was the case with the DPP. More importantly, it uses an open visit system in which users get a core set of materials for home review that is then reviewed in facilitated group sessions. In this regard, the group session content is not configured as a sequential series of sessions delivered in a specific order, as was the case with the DPP. Moreover, participants can rejoin groups at any time that they choose. Weight Watchers also provides a sophisticated set of support materials online, using both phone apps (to help users track food consumption and points used) and a website program. The open attendance feature and the availability of online support should, in theory, facilitate long-term adherence.

Interventions

BEHAVIORALWeight Watchers

The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk.

BEHAVIORALNational Diabetes Education Program

Sponsors

WW International Inc
CollaboratorINDUSTRY
Indiana Clinical and Translational Sciences Institute
CollaboratorOTHER
National Diabetes Education Program
CollaboratorUNKNOWN
Indiana University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Persons age 18 and over * Determination of BMI ≥ 24 kg/m2; persons of Asian Descent BMI ≥ 23 kg/m2 * Completion of the 7-item ADA Diabetes Risk Assessment and an ADA risk score ≥ 5 * Persons with a value of 100mg/dl or greater will confer eligibility from a single drop of whole blood obtained by finger stick to assess casual capillary blood glucose (CCBG) concentration using One-Touch Ultra handheld glucometer. * Persons at high-risk for Impaired Glucose Tolerance (IGT), having an ADA Risk Score ≥5 and CCBG 110-199 mg/dl or an A1c ≥5.7%and \< 6.5%. * Women with a self-reported history of gestational diabetes with an A1c \<6.5% and/or CCBG \<199 mg/dl

Exclusion criteria

* Persons under the age of 18 * Persons with no evidence of pre-diabetes. * Persons who are pregnant or planning to become pregnant. * Person unable or unwilling to provide consent. * Screening attendees who have a known condition that could alter glucose metabolism (e.g. pregnancy; known diabetes; antipsychotic or steroid medications; certain diseases or other conditions including Cushing's syndrome, acromegaly, pheochromocytoma, chronic pancreatitis, or HIV.) * Heart attack, stroke or transient ischemic attack (TIA) in the past 6 months. * Uncontrolled hypertension: systolic \> 180 mm Hg or diastolic \>105 mm Hg. * Persons receiving treatment for cancer (excluding surgery alone) within the last 2 years(excluding skin cancer). * Chest pain. * Shortness of breath with minimal activity or at rest. * Unexplained dizziness or fainting with physical activity (exercise). * Chronic lung disease: Chronic Obstructive Pulmonary Disease (COPD) or asthma requiring home oxygen therapy (excluding sole use of a continuous positive airway pressure (CPAP) machine). * Current use of anti-diabetes medications for the treatment of diagnosed diabetes * Unable to communicate with research staff (including intervention staff). * Unable to read written English.

Design outcomes

Primary

MeasureTime frame
Changes in weight6, 12, 19 and 24 months from baseline

Secondary

MeasureTime frame
Changes in A1c6, 12, 19 and 24 months from baseline
Changes in systolic blood pressure6, 12, 19 and 24 months from baseline
Changes in total cholesterol6, 12, 19 and 24 months from baseline
Changes in HDL-cholesterol6, 12, 19 and 24 months from baseline

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026